Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Cefprozil Granule in Healthy Chinese Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female aged between 18 and 55 years old (including the critical value).~* The body mass index is in the range of 19-28 kg/m2 (including the critical value). The weight of male is not less than 50 kg, and that of female is not less than 45 kg (including the critical value).~* Subjects who had not any medical history of cardiovascular, digestive, respiratory, nervous, haemal diseases or hepatic/renal impairment.The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: physical examination, 12-lead ECG, vital sign measurements, and laboratory safety tests .~* The subjects have no family planning within 6 months and could select contraceptive method.~* Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.~* The subjects could complete the study accorrding to the protocol.~Exclusion Criteria:~* any history of hypersensitivity, needlesickness or idiosyncratic reactions to any food or drug, especially for penicillins or cephalosporins;~* hepatitis (including hepatitis B and C), positive screening results for AIDS or syphilis;~* any history of acute or chronic illness that might affect drug absorption, and/or metabolism;~* positive results for urine drug screening;~* any history of drug abuse in the past 5 years or drug use 3 months prior to screening;~* any history of alcohol abuse in the recent 2 years or moderate drinkers (drink more 2 units per day or 14 units per week);~* smoking more than 5 cigarettes per day during the 3 months prior to screening;~* blood donation, massive blood loss (\>400mL) or enrolled in other clinical trials 3 months prior to screening;~* any use of other prescription drugs (including contraceptive) 14 days prior to medication for this study;~* any use of prescription or over-the-counter drugs, functional vitamin, herbal/ alcohol products, grapefruit-containing or caffeine/xanthine-rich foodand beverages 48 h prior to medication for this study;~* the outcome of breath alcohol test \> 0mg /mL;~* dysphagia or having special dietary requirements;~* occurring acute disease in the screening period or before the medication;~* lactating or pregnant women;~* investigator-determined ineligibility.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- conference-Cefprozil for Suspension® (Type: EXPERIMENTAL): Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)
- test-cefprozil granule (Type: EXPERIMENTAL): cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete